58379-80-9

Usage

Uses

Used in Organic Synthesis:
1-Methyl-1-tosylmethyl isocyanide is used as a building block in organic synthesis for the preparation of various other compounds. Its unique isocyanide functional group allows for the formation of carbon-carbon and carbon-nitrogen bonds, making it a valuable reagent in the creation of complex organic molecules.
Used in Pharmaceutical Synthesis:
1-Methyl-1-tosylmethyl isocyanide is used as a versatile reagent in the synthesis of pharmaceuticals. Its ability to form crucial bonds in organic molecules makes it an essential component in the development of new drugs and medicinal compounds.
Used in Research and Development:
In the field of research and development, 1-Methyl-1-tosylmethyl isocyanide is utilized for exploring new chemical reactions and pathways. Its reactivity and potential toxicity make it a subject of interest for scientists studying the properties and applications of isocyanide compounds.

InChI:InChI=1/C10H11NO2S/c1-8-4-6-10(7-5-8)14(12,13)9(2)11-3/h4-7,9H,1-2H3

Upstream product

• 38622-91-2 [(p-methylphenyl)sulfonylmethyl]isonitrile 
• 74-88-4 methyl iodide 
• 58379-87-6 {1-[(4-methylphenyl)sulfonyl]ethyl}formamide 

Downstream Products

• 117267-31-9 1,3-bis(4-methyl-5-oxazolyl)benzene 
• 120286-64-8 1,4-bis<1-(4-chlorophenyl)-4-methyl-imidazolyl>benzene 
• 120286-63-7 1,4-bis<1-(4-bromophenyl)-4-methyl-imidazolyl>benzene 
• 97388-64-2 [4-Chloro-1-methyl-1-(toluene-4-sulfonyl)-butyl]-methylene-amine 
• 97388-60-8 2,6-diisocyano-2,6-ditosylheptane 
• 120934-79-4 methyl 2-methyl-4-(2-(phenylmethyl)-benzoyl)-1H-pyrrole-3-carboxylate 
• 117267-30-8 1,2-bis(4-methyl-5-oxazolyl)benzene 
• 23012-24-0 4-methyl-5-(4-nitro-phenyl)-oxazole 
• 5881-57-2 2-methyl-4-(4-nitro-phenyl)-pyrrole-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

INHIBITOR COMPOUNDS

The disclosure relates to heterocyclic compounds and methods for their preparation. The disclosure provides compounds that may have beneficial therapeutic activity in the treatment of a disease or condition mediated by excessive or otherwise undesirable Des1 and/or fibrotic activity.

COMPOUNDS AND USES THEREOF

The present disclosure features compounds and methods useful for the treatment of BAF complex-related disorders.

ATR INHIBITOR AND APPLICATION THEREOF

Disclosed are a compound as an ATR inhibitor and an application in preparing a drug as an ATR inhibitor. In particular, disclosed is a compound represented by formula (I) or an isomer or pharmaceutically acceptable salt thereof.

Catalytic Enantio- and Diastereoselective Mannich Addition of TosMIC to Ketimines

Chiral amines bearing a stereocenter in the α position are ubiquitous compounds with many applications in the pharmaceutical and agrochemical sectors, as well as in catalysis. Catalytic asymmetric Mannich additions represent a valuable method to access such compounds in enantioenriched form. This work reports the first enantio- and diastereoselective addition of commercially available p-toluenesulfonylmethyl isocyanide (TosMIC) to ketimines, affording 2-imidazolines bearing two contiguous stereocenters, one of which is fully-substituted, with high yields and excellent stereocontrol. The reaction, catalyzed by silver oxide and a dihydroquinine-derived N,P-ligand, is broad in scope, operationally simple, and scalable. Derivatization of the products provides enantioenriched vicinal diamines, precursors to NHC ligands and sp3-rich heterocyclic scaffolds. Computations are used to understand catalysis and rationalize stereoselectivity.

Pd(II)-Catalyzed [4 + 2] Heterocyclization Sequence for Polyheterocycle Generation

A new Pd(II)-catalyzed cascade sequence for the formation of polyheterocycles, from simple starting materials, is reported. The sequence is applicable to both indole and pyrrole substrates, and a range of substituents are tolerated. The reaction is thought to proceed by a Pd(II)-catalyzed C-H activated Heck reaction followed by a second Pd(II)-catalyzed aza-Wacker reaction with two Cu(II)-mediated Pd(0) turnovers per sequence. The sequence can be considered a formal [4 + 2] heterocyclization.

1-Trifluoromethylisoquinolines from α-Benzylated Tosylmethyl Isocyanide Derivatives in a Modular Approach

The preparation of various 1-trifluoromethylisoquinolines from α-benzylated tosylmethyl isocyanide derivatives and the commercial Togni reagent using a radical cascade is reported. The starting isocyanides are readily prepared in a modular sequence from commercial tosylmethyl isocyanide via sequential double α-alkylation, and the radical reaction proceeds under mild conditions with high efficiency without any transition-metal catalyst via electron catalysis. This valuable protocol has been successfully applied to the total synthesis of CF3-mansouramycin B.

Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von hippel-lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities

E3 ubiquitin ligases are attractive targets in the ubiquitin-proteasome system, however, the development of small-molecule ligands has been rewarded with limited success. The von Hippel-Lindau protein (pVHL) is the substrate recognition subunit of the VHL E3 ligase that targets HIF-1α for degradation. We recently reported inhibitors of the pVHL:HIF-1α interaction, however they exhibited moderate potency. Herein, we report the design and optimization, guided by X-ray crystal structures, of a ligand series with nanomolar binding affinities.

One-pot Van Leusen synthesis of 4,5-disubstituted oxazoles in ionic liquids

An efficient and mild protocol for the preparation of 4,5-disubstituted oxazoles through an improved one-pot van Leusen oxazole synthesis in ionic liquids is described. The oxazole products were prepared from tosylmethyl isocyanide (TosMIC), aliphatic hal

NOVEL IMIDAZOLE DERIVATIVES

The present invention relates to novel imidazole derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein R1 is halogen, C1-C4alkyl or C1-Cs

NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention relates to novel compounds having a xanthine oxidase inhibitory effect and an uricosuric effect and pharmaceutical compositions comprising the same as an active ingredient. That is, the present invention relates nitrogen-containing heterocyclic compounds represented by the following general formula (I): wherein Y1 represents N or C(R4) ; Y2 represents N or C(R5) ; R4 and R5 independently represent an alkyl group, a hydrogen atom etc. ; one of R1 and R2 represents an optionally substituted aryl group, an alkoxygroup or an optionally substituted heterocyclic group; the other of R1 and R2 represents a haloalkyl group, a cyanogroup, ahalogenatometc.; and R3 represents a 5-tetrazolyl group or a carboxy group, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same as an active ingredient.